Feuchtinger, Tobias and Bader, Peter and Subklewe, Marion and Breidenbach, Maike and Willier, Semjon and Metzler, Markus and Goekbuget, Nicola and Hauer, Julia and Mueller, Fabian and Schlegel, Paul-Gerhardt and Fruehwald, Michael and Schmid, Christoph and Troeger, Anja and Baldus, Claudia and Meisel, Roland and Kuenkele, Annette and Topp, Max and Bourquin, Jean-Pierre and Cario, Gunnar and von Stackelberg, Arend and Peters, Christina (2024) Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults. HAEMATOLOGICA, 109 (12). pp. 3892-3903. ISSN 0390-6078, 1592-8721
Full text not available from this repository. (Request a copy)Abstract
The ongoing development of immunotherapies, including chimeric antigen receptor (CAR) T cells, has revolutionized cancer treatment. In pediatric relapsed/refractory B-lineage acute leukemia antiCD19-CAR induce impressive initial response rates, with event-free survival plateauing at 30-50% according to long-term follow-up data. During the interval between diagnosis of relapse or refractoriness and CAR T-cell infusion, patients require a bridging therapy. To date, this therapy has consisted of highly variable approaches based on local experience. Here, in an European collaborative effort of pediatric and adult hematologists, we summarize current knowledge with the aim of establishing guidance for bridging therapy. We discuss treatment strategies for different subgroups of patients, the advantages and disadvantages of low- and high-intensity regimens, and the potential impact of bridging therapy on outcomes after CAR T-cell infusion. This guidance is a step towards cross-institutional harmonization of bridging therapy, including personalized approaches. This will allow better comparability of clinical data and increase the level of evidence for the treatment of children and young adults with relapsed/refractory B-lineage acute leukemia until they can receive CAR T-cell infusion.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INOTUZUMAB OZOGAMICIN; PHASE-II; TISAGENLECLEUCEL; ADOLESCENTS; MANAGEMENT; TRIAL; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 Aug 2025 06:14 |
| Last Modified: | 06 Aug 2025 06:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65688 |
Actions (login required)
 |
View Item |
